{"id":62660,"date":"2026-04-08T21:43:55","date_gmt":"2026-04-08T13:43:55","guid":{"rendered":"https:\/\/flcube.com\/?p=62660"},"modified":"2026-04-08T21:43:56","modified_gmt":"2026-04-08T13:43:56","slug":"ascletis-pharma-advances-oral-glp-1r-amylin-receptor-dual-agonist-combination-asc30-asc39-for-obesity-targeting-q3-fda-ind-submission","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62660","title":{"rendered":"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission"},"content":{"rendered":"\n<p><strong>Ascletis Pharma Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG: 1672<\/a>)<\/strong> announced the selection of a <strong>fixed-dose combination (FDC)<\/strong> of <strong>ASC30 and ASC39<\/strong> for clinical development in <strong>obesity<\/strong>, with an <strong>Investigational New Drug (IND)<\/strong> application slated for submission to the <strong>U.S. Food and Drug Administration (FDA)<\/strong> in <strong>Q3 2026<\/strong>. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-program-overview\">Development Program Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ascletis Pharma Inc. (HKG: 1672)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>ASC30 (GLP-1R agonist) + ASC39 (amylin receptor agonist)<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Fixed-dose combination (FDC), oral administration<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Obesity<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>FDA IND submission targeted for Q3 2026<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Pre-IND, advancing to clinical development<\/td><\/tr><tr><td><strong>Key Differentiation<\/strong><\/td><td>Dual mechanism with improved tolerability profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-component-drug-profiles\">Component Drug Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-asc30-oral-glp-1-receptor-agonist\">ASC30: Oral GLP-1 Receptor Agonist<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Stage<\/strong>: Ready for Phase III clinical development<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral small-molecule formulation<\/li>\n\n\n\n<li><strong>Tolerability Advantage<\/strong>: <strong>50% lower vomiting incidence<\/strong> versus orforglipron in non-head-to-head weekly titration studies<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: GLP-1 receptor activation promoting satiety and glucose regulation<\/li>\n\n\n\n<li><strong>Dosing Flexibility<\/strong>: Weekly titration protocol optimized for patient adherence<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-asc39-amylin-receptor-agonist\">ASC39: Amylin Receptor Agonist<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Potent oral small-molecule amylin receptor agonist with <strong>selectivity for amylin receptors<\/strong><\/li>\n\n\n\n<li><strong>Preclinical Performance<\/strong>: Demonstrated efficacy <strong>similar to eloralintide<\/strong> in preclinical models<\/li>\n\n\n\n<li><strong>Target Validation<\/strong>: Amylin pathway complements GLP-1 effects through distinct but synergistic mechanisms<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: Selected as clinical development candidate based on preclinical data package<\/li>\n\n\n\n<li><strong>Oral Bioavailability<\/strong>: Small-molecule format enabling convenient oral dosing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale-amp-dual-mechanism-strategy\">Scientific Rationale &amp; Dual-Mechanism Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-complementary-pathways\">Complementary Pathways<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 Effects<\/strong>: Promotes satiety, slows gastric emptying, improves insulin sensitivity<\/li>\n\n\n\n<li><strong>Amylin Effects<\/strong>: Reduces food intake through central nervous system pathways, suppresses glucagon secretion<\/li>\n\n\n\n<li><strong>Synergistic Potential<\/strong>: Dual activation may provide superior weight loss versus single-mechanism approaches<\/li>\n\n\n\n<li><strong>Tolerability Optimization<\/strong>: ASC30&#8217;s improved GI profile may offset typical amylin-related side effects<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Administration<\/strong>: Both components are oral small molecules, avoiding injectable formulations<\/li>\n\n\n\n<li><strong>Fixed-Dose Convenience<\/strong>: Single-pill combination enhances patient compliance versus separate medications<\/li>\n\n\n\n<li><strong>Tolerability Focus<\/strong>: Specifically designed to address gastrointestinal side effects limiting current therapies<\/li>\n\n\n\n<li><strong>Novel Combination<\/strong>: First-in-class potential for this specific GLP-1\/amylin receptor dual approach<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-obesity-therapeutics-evolution\">Obesity Therapeutics Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 Dominance<\/strong>: Current market led by injectable GLP-1 agonists (Wegovy, Zepbound, Mounjaro)<\/li>\n\n\n\n<li><strong>Oral Gap<\/strong>: Significant unmet need for effective oral alternatives to injections<\/li>\n\n\n\n<li><strong>Combination Trend<\/strong>: Industry moving toward multi-hormone approaches for enhanced efficacy<\/li>\n\n\n\n<li><strong>Tolerability Challenge<\/strong>: GI side effects remain primary barrier to treatment adherence and dose escalation<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-competitors\">Key Competitors<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eli Lilly<\/strong>: Tirzepatide (GLP-1\/GIP dual agonist), orforglipron (oral GLP-1)<\/li>\n\n\n\n<li><strong>Novo Nordisk<\/strong>: Semaglutide (GLP-1), oral semaglutide development<\/li>\n\n\n\n<li><strong>Amgen<\/strong>: MariTide (amylin analog) in development<\/li>\n\n\n\n<li><strong>Other Oral Candidates<\/strong>: Multiple companies advancing oral GLP-1 and combination approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-ascletis\">Strategic Implications for Ascletis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-portfolio-diversification\">Portfolio Diversification<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beyond Antivirals<\/strong>: Expands beyond traditional antiviral focus into metabolic disease<\/li>\n\n\n\n<li><strong>U.S. Market Entry<\/strong>: FDA IND represents strategic entry into largest pharmaceutical market<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Demonstrates capability to develop complex combination therapies<\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Attractive asset for potential global partnership or licensing<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-timeline-expectations\">Development Timeline Expectations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Q3 2026<\/strong>: IND submission to FDA<\/li>\n\n\n\n<li><strong>Q4 2026\/Q1 2027<\/strong>: Phase I initiation pending IND acceptance<\/li>\n\n\n\n<li><strong>Phase II<\/strong>: Expected to evaluate combination versus monotherapy components<\/li>\n\n\n\n<li><strong>Phase III<\/strong>: Potential accelerated pathway based on mechanism validation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-outlook-amp-market-opportunity\">Commercial Outlook &amp; Market Opportunity<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-addressable-market\">Addressable Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Prevalence<\/strong>: Over 100 million adults with obesity in the U.S. alone<\/li>\n\n\n\n<li><strong>Treatment Penetration<\/strong>: Current GLP-1 therapies reaching only single-digit percentage of eligible patients<\/li>\n\n\n\n<li><strong>Oral Premium<\/strong>: Significant patient preference for oral versus injectable administration<\/li>\n\n\n\n<li><strong>Pricing Power<\/strong>: Novel mechanisms command premium pricing in obesity market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revenue-potential\">Revenue Potential<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Sales<\/strong>: Multi-billion dollar potential if successful in Phase III<\/li>\n\n\n\n<li><strong>Global Rights<\/strong>: Assuming worldwide rights retained by Ascletis<\/li>\n\n\n\n<li><strong>Manufacturing Advantage<\/strong>: Small-molecule oral drugs typically have lower COGS than biologics<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: Obesity indication increasingly covered by commercial insurers<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-risk-assessment-amp-challenges\">Risk Assessment &amp; Challenges<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-risks\">Development Risks<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IND Acceptance<\/strong>: Standard regulatory review process with potential requests for additional data<\/li>\n\n\n\n<li><strong>Clinical Translation<\/strong>: Preclinical efficacy must translate to human patients<\/li>\n\n\n\n<li><strong>Combination Safety<\/strong>: Potential for unexpected drug-drug interactions or additive side effects<\/li>\n\n\n\n<li><strong>Dosing Optimization<\/strong>: Complex titration schedules for dual-mechanism approach<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-risks\">Competitive Risks<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Disadvantage<\/strong>: Multiple competitors already in late-stage development<\/li>\n\n\n\n<li><strong>Pricing Pressure<\/strong>: Potential for competitive pricing strategies from established players<\/li>\n\n\n\n<li><strong>Patent Landscape<\/strong>: Complex intellectual property environment in GLP-1 and amylin space<\/li>\n\n\n\n<li><strong>Market Saturation<\/strong>: Risk of market crowding by multiple similar mechanisms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-development-pathway\">Forward Development Pathway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IND Preparation<\/strong>: Final toxicology and manufacturing studies for Q3 submission<\/li>\n\n\n\n<li><strong>Phase I Design<\/strong>: Likely single and multiple ascending dose studies in healthy volunteers<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Initial obesity studies in BMI \u226530 or \u226527 with comorbidities<\/li>\n\n\n\n<li><strong>Endpoint Selection<\/strong>: Weight loss percentage, safety, and tolerability as primary measures<\/li>\n\n\n\n<li><strong>Combination Strategy<\/strong>: Direct comparison of FDC versus individual components<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IND submission, clinical development, and commercial potential. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040700222_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040700222_c.\"><\/object><a id=\"wp-block-file--media-6058a957-73ed-4773-a7cb-640c61dc8468\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040700222_c.pdf\">2026040700222_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040700222_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6058a957-73ed-4773-a7cb-640c61dc8468\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[189,980],"class_list":["post-62660","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-ascletis-pharma","tag-hkg-1672"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30 and ASC39 for clinical development in obesity, with an Investigational New Drug (IND) application slated for submission to the U.S. Food and Drug Administration (FDA) in Q3 2026. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62660\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30 and ASC39 for clinical development in obesity, with an Investigational New Drug (IND) application slated for submission to the U.S. Food and Drug Administration (FDA) in Q3 2026. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62660\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T13:43:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T13:43:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62660#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62660\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Pharma Advances Oral GLP-1R\\\/Amylin Receptor Dual Agonist Combination ASC30\\\/ASC39 for Obesity, Targeting Q3 FDA IND Submission\",\"datePublished\":\"2026-04-08T13:43:55+00:00\",\"dateModified\":\"2026-04-08T13:43:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62660\"},\"wordCount\":791,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"HKG: 1672\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62660#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62660\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62660\",\"name\":\"Ascletis Pharma Advances Oral GLP-1R\\\/Amylin Receptor Dual Agonist Combination ASC30\\\/ASC39 for Obesity, Targeting Q3 FDA IND Submission - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T13:43:55+00:00\",\"dateModified\":\"2026-04-08T13:43:56+00:00\",\"description\":\"Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30 and ASC39 for clinical development in obesity, with an Investigational New Drug (IND) application slated for submission to the U.S. Food and Drug Administration (FDA) in Q3 2026. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62660#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62660\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62660#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Pharma Advances Oral GLP-1R\\\/Amylin Receptor Dual Agonist Combination ASC30\\\/ASC39 for Obesity, Targeting Q3 FDA IND Submission\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30 and ASC39 for clinical development in obesity, with an Investigational New Drug (IND) application slated for submission to the U.S. Food and Drug Administration (FDA) in Q3 2026. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62660","og_locale":"en_US","og_type":"article","og_title":"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission","og_description":"Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30 and ASC39 for clinical development in obesity, with an Investigational New Drug (IND) application slated for submission to the U.S. Food and Drug Administration (FDA) in Q3 2026. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.","og_url":"https:\/\/flcube.com\/?p=62660","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T13:43:55+00:00","article_modified_time":"2026-04-08T13:43:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62660#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62660"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission","datePublished":"2026-04-08T13:43:55+00:00","dateModified":"2026-04-08T13:43:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62660"},"wordCount":791,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","HKG: 1672"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62660#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62660","url":"https:\/\/flcube.com\/?p=62660","name":"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T13:43:55+00:00","dateModified":"2026-04-08T13:43:56+00:00","description":"Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30 and ASC39 for clinical development in obesity, with an Investigational New Drug (IND) application slated for submission to the U.S. Food and Drug Administration (FDA) in Q3 2026. The dual-mechanism approach combines ASC30, an oral GLP-1 receptor agonist with superior gastrointestinal tolerability, and ASC39, a potent amylin receptor agonist with demonstrated preclinical efficacy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62660#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62660"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62660#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Pharma Advances Oral GLP-1R\/Amylin Receptor Dual Agonist Combination ASC30\/ASC39 for Obesity, Targeting Q3 FDA IND Submission"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62660"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62660\/revisions"}],"predecessor-version":[{"id":62663,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62660\/revisions\/62663"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}